Rana Elmaghraby, Elizabeth Blank, Makoto Miyakoshi, Donald L Gilbert, Steve W Wu, Travis Larsh, Grace Westerkamp, Yanchen Liu, Paul S Horn, Craig A Erickson, Ernest V Pedapati
{"title":"Probing the Neurodynamic Mechanisms of Cognitive Flexibility in Depressed Individuals with Autism Spectrum Disorder.","authors":"Rana Elmaghraby, Elizabeth Blank, Makoto Miyakoshi, Donald L Gilbert, Steve W Wu, Travis Larsh, Grace Westerkamp, Yanchen Liu, Paul S Horn, Craig A Erickson, Ernest V Pedapati","doi":"10.1089/cap.2024.0109","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Introduction:</i></b> Autism spectrum disorder (ASD) is characterized by deficits in social behavior and executive function (EF), particularly in cognitive flexibility. Whether transcranial magnetic stimulation (TMS) can improve cognitive outcomes in patients with ASD remains an open question. We examined the acute effects of prefrontal TMS on cortical excitability and fluid cognition in individuals with ASD who underwent TMS for refractory major depression. <b><i>Methods:</i></b> We analyzed data from an open-label pilot study involving nine participants with ASD and treatment-resistant depression who received 30 sessions of accelerated theta burst stimulation of the dorsolateral prefrontal cortex, either unilaterally or bilaterally. Electroencephalography data were collected at baseline and 1, 4, and 12-weeks posttreatment and analyzed using a mixed-effects linear model to assess changes in regional cortical excitability using three models of spectral parametrization. Fluid cognition was measured using the National Institutes of Health Toolbox Cognitive Battery. <b><i>Results:</i></b> Prefrontal TMS led to a decrease in prefrontal cortical excitability and an increase in right temporoparietal excitability, as measured using spectral exponent analysis. This was associated with a significant improvement in the NIH Toolbox Fluid Cognition Composite score and the Dimensional Change Card Sort subtest from baseline to 12 weeks posttreatment (t = 3.79, p = 0.005, <i>n</i> = 9). Improvement in depressive symptomatology was significant (HDRS-17, F (3, 21) = 28.49, <i>p</i> < 0.001) and there was a significant correlation between cognitive improvement at week 4 and improvement in depression at week 12 (r = 0.71, <i>p</i> = 0.05). <b><i>Conclusion:</i></b> These findings link reduced prefrontal excitability in patients with ASD and improvements in cognitive flexibility. The degree to which these mechanisms can be generalized to ASD populations without Major Depressive Disorder remains a compelling question for future research.</p>","PeriodicalId":15277,"journal":{"name":"Journal of child and adolescent psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of child and adolescent psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cap.2024.0109","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Autism spectrum disorder (ASD) is characterized by deficits in social behavior and executive function (EF), particularly in cognitive flexibility. Whether transcranial magnetic stimulation (TMS) can improve cognitive outcomes in patients with ASD remains an open question. We examined the acute effects of prefrontal TMS on cortical excitability and fluid cognition in individuals with ASD who underwent TMS for refractory major depression. Methods: We analyzed data from an open-label pilot study involving nine participants with ASD and treatment-resistant depression who received 30 sessions of accelerated theta burst stimulation of the dorsolateral prefrontal cortex, either unilaterally or bilaterally. Electroencephalography data were collected at baseline and 1, 4, and 12-weeks posttreatment and analyzed using a mixed-effects linear model to assess changes in regional cortical excitability using three models of spectral parametrization. Fluid cognition was measured using the National Institutes of Health Toolbox Cognitive Battery. Results: Prefrontal TMS led to a decrease in prefrontal cortical excitability and an increase in right temporoparietal excitability, as measured using spectral exponent analysis. This was associated with a significant improvement in the NIH Toolbox Fluid Cognition Composite score and the Dimensional Change Card Sort subtest from baseline to 12 weeks posttreatment (t = 3.79, p = 0.005, n = 9). Improvement in depressive symptomatology was significant (HDRS-17, F (3, 21) = 28.49, p < 0.001) and there was a significant correlation between cognitive improvement at week 4 and improvement in depression at week 12 (r = 0.71, p = 0.05). Conclusion: These findings link reduced prefrontal excitability in patients with ASD and improvements in cognitive flexibility. The degree to which these mechanisms can be generalized to ASD populations without Major Depressive Disorder remains a compelling question for future research.
自闭症谱系障碍(ASD)以社会行为和执行功能(EF)的缺陷为特征,尤其是认知灵活性的缺陷。经颅磁刺激(TMS)是否能改善ASD患者的认知预后仍是一个悬而未决的问题。我们研究了前额叶经颅磁刺激对接受经颅磁刺激治疗难治性重度抑郁症的ASD患者皮质兴奋性和流体认知的急性影响。方法:我们分析了一项开放标签试点研究的数据,该研究涉及9名ASD和难治性抑郁症患者,他们接受了30次单侧或双侧前额皮质背外侧加速θ波爆发刺激。在基线和治疗后1、4和12周收集脑电图数据,并使用混合效应线性模型分析,使用三种谱参数化模型评估区域皮层兴奋性的变化。流体认知使用美国国立卫生研究院工具箱认知电池进行测量。结果:经颅磁刺激导致前额叶皮层兴奋性降低,右侧颞顶兴奋性增加。这与NIH工具箱流体认知综合评分和维度变化卡分类子测试从基线到治疗后12周的显著改善相关(t = 3.79, p = 0.005, n = 9)。抑郁症状的改善显著(HDRS-17, F (3,21) = 28.49, p < 0.001),第4周认知改善与第12周抑郁改善之间存在显著相关性(r = 0.71, p = 0.05)。结论:这些发现将ASD患者前额叶兴奋性降低与认知灵活性改善联系起来。这些机制在多大程度上可以推广到没有重度抑郁症的ASD人群,这仍然是未来研究的一个引人注目的问题。
期刊介绍:
Journal of Child and Adolescent Psychopharmacology (JCAP) is the premier peer-reviewed journal covering the clinical aspects of treating this patient population with psychotropic medications including side effects and interactions, standard doses, and research on new and existing medications. The Journal includes information on related areas of medical sciences such as advances in developmental pharmacokinetics, developmental neuroscience, metabolism, nutrition, molecular genetics, and more.
Journal of Child and Adolescent Psychopharmacology coverage includes:
New drugs and treatment strategies including the use of psycho-stimulants, selective serotonin reuptake inhibitors, mood stabilizers, and atypical antipsychotics
New developments in the diagnosis and treatment of ADHD, anxiety disorders, schizophrenia, autism spectrum disorders, bipolar disorder, eating disorders, along with other disorders
Reports of common and rare Treatment Emergent Adverse Events (TEAEs) including: hyperprolactinemia, galactorrhea, weight gain/loss, metabolic syndrome, dyslipidemia, switching phenomena, sudden death, and the potential increase of suicide. Outcomes research.